

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Three Months Ended March 31,	
	2018	2017
Grant and collaboration revenues	\$ 221	\$ 296
Operating expenses:		
Research and development	487	552
General and administrative	357	292
	844	844
Loss from operations	(623)	(548)
Other income (expense), net	1	-
	\$ (622)	\$ (548)
Net loss	\$ (622)	\$ (548)
Net loss per common share	\$ (0.01)	\$ (0.01)
Weighted average shares outstanding	124,170	55,351

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	March 31, 2018	Dec. 31, 2017
Assets:		
Cash and cash equivalents	\$ 571	\$ 313
Other current assets	231	135
Total current assets	802	448
Property, net	26	31
Other assets	11	11
Total assets	\$ 839	\$ 490
Liabilities and stockholders' equity (deficiency)		
Current liabilities	\$ 919	\$ 811
Note payable, net of current portion	49	-
Stockholders' equity (deficiency)	(129)	(321)
Total liabilities and stockholders' equity (deficiency)	\$ 839	\$ 490
Shares Outstanding	141,737	106,737